Inactive

This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT (as prescribed in FAR 6.302-1(a)(2). This notice is for informational and planning purposes and does not constitute a solicitation. The Offic... This is a NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT (as prescribed in FAR 6.302-1(a)(2). This notice is for informational and planning purposes and does not constitute a solicitation. The Office of the Assistant Secretary for Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS), intends to award a sole source firm fixed contract to Emergent Biosolutions Inc., 50 & 90 Shawmut Road, Canton, MA 02021 for the acquisition of Wetvax Potency testing. The statutory authority for this sole source acquisition is 10 U.S.C 2304(c) (1) in accordance with FAR Part 6.302-1- only one responsible source and no other supplies or services will satisfy the agency requirement. The NAICS code for this procurement is 325412, Pharmaceutical Preparation Manufacturing. The period of performance for this procurement is 5/15/2021-9/15/2021. The Office of the Assistant Secretary for Preparedness and Response (ASPR) leads the nation in preventing, preparing for, responding to, and recovering from the adverse health effects of emergencies and disasters by supporting our communities’ ability to withstand adversity, strengthening our health and response systems, and enhancing national health security. The Division of Strategic National Stockpile (DSNS) is responsible for stockpiling and deploying pharmaceuticals and medical supplies needed during a public health response. During a public health emergency, federal supplies of medications used to treat or prevent illness may need to be distributed and dispensed to people throughout the country. The purpose of this requirement is to perform potency testing using an FDA qualified and validated vaccinia based potency assay on samples of Wetvax provided by the ASPR/SNS. The following technical specifications are necessary to fulfill this requirement: The vendor must have an FDA qualified and validated vaccinia virus potency test which is currently being used to titer the potency of all current lots of the ACAM2000 Smallpox vaccine. The vendor shall test must be identical to the requirements outlined in protocol currently being used by Emergent BioSolutions, Canton, MA. As a result of this Notice of Intent, no competitive solicitation will be posted on FedBizOpps. We will issue only one solicitation to Emergent Biosolutions Inc. However, all responsible sources that believe they can meet these requirements may submit their capabilities/qualifications statement. All capabilities/qualification statements must be received NO LATER THAN April 21, 2021 at 2:00PM EST and sent to Kimberly Golden via email ONLY at IXM9@cdc.gov with the solicitation number #75A50120OS274465. referenced in the subject line. TELEPHONE CALLS WILL NOT BE ACCEPTED. A determination by the Government not to compete this proposed action will be based on responses to this notice and are solely within the discretion of the Contracting Officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Place of Performance: Emergent Biosolutions Inc. 50 & 90 Shawmut Road Canton, MA 02021